The outlook of companies tied to the drug's past presents a complex investment picture . While the initial boom generated substantial returns , generic alternatives have significantly impacted market share . Investing in connected pharmaceutical firms now requires a thorough assessment of patent safeguards, evolving healthcare changes, and the poss